Adam Crystal
Tango Therapeutics (United States) · 123 works · 4,694 citations · h-index 19
Top works
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- Prospects for combining targeted and conventional cancer therapy with immunotherapy
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114
- A locus affecting obesity in human chromosome region 10p12
- Membrane Topology of γ-Secretase Component PEN-2
- The Transmembrane Domain Region of Nicastrin Mediates Direct Interactions with APH-1 and the γ-Secretase Complex
- Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies
- New targets in advanced NSCLC: EML4-ALK.
- Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
- Membrane Topology and Nicastrin-enhanced Endoproteolysis of APH-1, a Component of the γ-Secretase Complex
- Presenilin Modulates Pen-2 Levels Posttranslationally by Protecting It from Proteasomal Degradation
- No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease
- A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
- Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients
- Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer
- N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53
- Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers